APG Asset Management N.V. Purchases Shares of 97,300 Exact Sciences Co. (NASDAQ:EXAS)

APG Asset Management N.V. acquired a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 97,300 shares of the medical research company's stock, valued at approximately $5,280,000. APG Asset Management N.V. owned about 0.05% of Exact Sciences as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in EXAS. Asset Planning Inc acquired a new stake in shares of Exact Sciences in the fourth quarter valued at approximately $40,000. Modus Advisors LLC acquired a new stake in Exact Sciences during the 4th quarter valued at $43,000. AlphaQuest LLC raised its holdings in shares of Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after acquiring an additional 913 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences in the fourth quarter valued at $66,000. Finally, Quantinno Capital Management LP acquired a new stake in shares of Exact Sciences during the third quarter valued at $223,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Exact Sciences Stock Down 0.1 %

Shares of EXAS stock traded down $0.06 during trading hours on Thursday, reaching $42.20. The company had a trading volume of 1,007,390 shares, compared to its average volume of 2,591,371. The stock's fifty day simple moving average is $46.28 and its 200 day simple moving average is $55.39. The company has a market capitalization of $7.84 billion, a P/E ratio of -7.57 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a twelve month low of $39.97 and a twelve month high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, sell-side analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EXAS. Piper Sandler cut their target price on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Guggenheim reissued a "buy" rating and issued a $60.00 price objective on shares of Exact Sciences in a research report on Friday, April 11th. Mizuho began coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price on the stock. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, Barclays reduced their price target on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $69.25.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.